ANTHONY KELADA: Open Payments
NPI 1659790624 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$407 in 16 payments from 8 companies in 2025. Trend: 2023 $343 · 2024 $607 · 2025 $407
Food & beverage: $407
| Company | Payments | Amount |
|---|---|---|
| Amneal Pharmaceuticals LLC | 5 | $123 |
| ACADIA Pharmaceuticals Inc | 3 | $73 |
| LivaNova USA, Inc. | 2 | $60 |
| SK Life Science, Inc. | 2 | $57 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| ABBVIE INC. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
Products named: DAYBUE, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, CREXONT, RYTARY, SPRAVATO, ONGENTYS, VRAYLAR, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
